Patrys Limited (ASX:PAB)

Market Cap	2.06M
Revenue (ttm)	1.46M
Net Income (ttm)	-3.11M
Shares Out	2.06B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,052,603
Average Volume	872,664
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0010 - 0.0080
Beta	0.36
RSI	40.61
Earnings Date	May 22, 2025

About Patrys

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. The company dvelops Deoxymab 3E10 also called PAT-DX1 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents such as radiation and many chemotherapy drugs. In addition, it develops PAT-DX3, a full-sized antibody that has DNA-targeting properties of PAT-DX1, but different pharmaceutic properties, such as tissue distributio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 10
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PAB

Financial Performance

In 2024, Patrys's revenue was 1.39 million, a decrease of -51.11% compared to the previous year's 2.85 million. Losses were -3.54 million, -49.88% less than in 2023.